

# 해외 바이오의약품 임상 현황 (2019.12.24~2020.01.06)

한국바이오의약품협회, 2020.1.7.  
출처: ClinicalTrials.gov

## ○ 미국 71건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04208958	Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer	Metastatic Cancer Melanoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Colorectal Cancer	Biological: VE800 Drug: Nivolumab Drug: Vancomycin Oral Capsule	Vedanta Biosciences, Inc. Bristol-Myers Squibb (BMS)	Phase 1 Phase 2
NCT04205656	Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction	Osteoarthritis, Knee	Biological: Leukocyte-Poor Platelet Rich Plasma (LP-PRP) Biological: Bone Marrow Concentrate (BMC) Other: Control group (Placebo)	Steadman Philippon Research Institute United States Department of Defense Office of Naval Research (ONR)	Phase 1 Phase 2
NCT04200989	Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy	Food Allergy Peanut	Biological: Peanut allergen	Scripps Health The Scripps Research Institute	Phase 1 Phase 2
NCT04121442	Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors	Solid Tumor, Adult	Biological: Isunakinra Biological: PD-(L)1 Inhibitor	Buzzard Pharmaceuticals Baylor Research Institute	Phase 1 Phase 2
NCT04083898	Isatuximab, Bendamustine, and Prednisone in Penta-Refractory Multiple Myeloma	Multiple Myeloma	Biological: Isatuximab Drug: Bendamustine Drug: Prednisone	Washington University School of Medicine Sanofi	Phase 1 Phase 2
NCT04074967	Study of ARRY-614 Plus Either Nivolumab or Ipilimumab	Renal Cell Carcinoma Melanoma Solid Tumor	Drug: Phase Ib ARRY-614 + nivolumab Drug: Phase Ib ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + ipilimumab Drug: Phase II ARRY-614 + nivolumab (melanoma) Drug: Phase II ARRY-614 + nivolumab (RCC)	Jason J. Luke, MD Array BioPharma University of Pittsburgh	Phase 1 Phase 2
NCT04046107	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	Hepatitis B Virus	Biological: Cemiplimab	National Institute of Allergy and Infectious Diseases (NIAID) Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT04035109	Anakinra as a Rescue Treatment for Allergic Inflammation	Asthma, Allergic	Drug: Anakinra Drug: Preservative-free 0.9% sodium chloride (Placebo) Biological: House dust mite allergen Biological: Cat hair allergen	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 Phase 2
NCT03851081	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blasts 5 Percent or More of Bone Marrow Nucleated Cells Blasts 5 Percent or More of Peripheral Blood White Cells CD22 Positive Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells Lymphoblasts 20 Percent or More of Peripheral Blood White Cells Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia	Biological: Inotuzumab Ozogamicin Other: Quality-of-Life Assessment Drug: Vincristine Sulfate Liposome	Roswell Park Cancer Institute National Cancer Institute (NCI) Pfizer	Phase 1 Phase 2
NCT03654040	Liver Transplantation With Tregs at UCSF	Liver Transplant	Biological: arTreg Procedure: leukapheresis Drug: cyclophosphamide Drug: mesna Drug: everolimus	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN)	Phase 1 Phase 2
NCT03597594	Haplocompatible Transplant Using TCR Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Severe Combined Immunodeficiency	Drug: Anti-thymocyte globulin (rabbit) Drug: Busulfan Drug: Fludarabine Drug: Thiotepa Device: CliniMACS Other: Donor Lymphocyte Infusion	St. Jude Children's Research Hospital	Phase 1 Phase 2
NCT03520751	Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A	Charcot-Marie-Tooth Neuropathy Type 1A	Drug: scAAV1.tMCK.NTF3	Nationwide Children's Hospital	Phase 1 Phase 2
NCT03214666	GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE?? for High Risk Heme Malignancies	High-risk Myelodysplastic Syndromes Acute Myelogenous Leukemia Systemic Mastocytosis Mast Cell Leukemia	Drug: GTB-3550 TriKE™Phase I Drug: GTB-3550 TriKE™Phase II	GT Biopharma, Inc.	Phase 1 Phase 2
NCT02229175	Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema	Diabetic Macular Edema	Drug: bevacizumab Device: PASCAL Endpoint Management (EpM) Laser treatment	University of California, San Francisco	Phase 2 Phase 3
NCT04142983	Tdap Vaccine Safety for Plasma Donors	Tetanus	Biological: Adacel	GCAM Inc.	Phase 2 Phase 3
NCT03576963	Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer	Colorectal Adenocarcinoma CpG Island Methylator Phenotype Metastatic Microsatellite Stable Colorectal Carcinoma Refractory Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Drug: Guadecitabine Biological: Nivolumab	University of Southern California National Cancer Institute (NCI) Bristol-Myers Squibb Astex Pharmaceuticals, Inc.	Phase 1 Phase 2
NCT04214886	CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies	B-Cell Acute Lymphoblastic Leukemia, Adult B-cell Lymphoma Refractory B-cell Lymphoma Recurrent	Drug: Fludarabine Drug: Cyclophosphamide Biological: CD19-CD34 CAR transduced T cells	Loyola University Leukemia Research Foundation	Phase 1
NCT04205838	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Progressive Disease Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleuce Drug: Cyclophosphamide Drug: Fludarabine Phosphate	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04201873	Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma	Recurrent Glioblastoma	Biological: Dendritic Cell Tumor Cell Lysate Vaccine Biological: Pembrolizumab Other: Placebo Administration Drug: Poly ICLC	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Merck Sharp & Dohme Corp. Phase One Foundation	Phase 1
NCT04199169	Safety and Immunogenicity of a Nipah Virus Vaccine	Nipah Virus Infection	Biological: HeV-sG-V Biological: Normal Saline Placebo	Profectus BioSciences, Inc. PATH Coalition for Epidemic Preparedness Initiative (CEPI) Cincinnati Children's Hospital Medical Center (CCHMC)	Phase 1
NCT04197310	Cabozantinib and Nivolumab for Carcinoid Tumors	Carcinoid Tumor Carcinoid Tumor of GI System Neuroendocrine Tumors	Drug: Nivolumab Drug: Cabozantinib	Dana-Farber Cancer Institute Bristol-Myers Squibb Exelixis	Phase 2

## 해외 바이오의약품 임상 현황 (2019.12.24~2020.01.06)

한국바이오의약품협회, 2020.1.7.  
출처: ClinicalTrials.gov

NCT04197219	Pembrolizumab With Axitinib in Recurrent Endometrial Cancer	Recurrent Endometrial Cancer	Drug: Pembrolizumab Drug: Axitinib	Haider Mahdi Case Comprehensive Cancer Center	Phase 2
NCT04187872	LITT and Pembrolizumab in Recurrent Brain Metastasis	Melanoma Non-small Cell Lung Carcinoma (NSCLC) Renal Cell Carcinoma (RCC) Brain Metastases	Combination Product: LITT + Pembrolizumab	University of Florida Monteris Medical	Phase 1
NCT04177004	Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplant Recipient Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Etoposide Radiation: Fractionated Stereotactic Radiation Therapy Drug: Goat Milk Biological: Palifermin Drug: Sirolimus Drug: Tacrolimus	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT04171219	Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers	Advanced Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm	Biological: Pembrolizumab Drug: Talabostat Drug: Talabostat Mesylate	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04154943	Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	Drug: Cemiplimab	Regeneron Pharmaceuticals	Phase 2
NCT04150900	1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck	Squamous Cell Carcinoma	Drug: Bavituximab Drug: Pembrolizumab	University of Maryland, Baltimore	Phase 2
NCT04149821	Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy	Chronic Lymphocytic Leukemia CLL Progression CLL/SLL	Drug: Umbralisib Drug: Ublituximab	Weill Medical College of Cornell University TG Therapeutics, Inc.	Phase 2
NCT04149275	Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma	Carcinosarcoma of Ovary Carcinosarcoma of Uterus Carcinosarcoma of Vagina	Drug: Cabozantinib Drug: Ipilimumab Drug: Nivolumab	University of Alabama at Birmingham	Phase 2
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IVD Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM BioPharma	Phase 2
NCT04117087	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Colorectal Cancer Pancreatic Cancer	Drug: KRAS peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04116073	INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer	Pancreatic Cancer Non-resectable Pancreatic Cancer Metastatic	Drug: INCMGA00012 (PD-1 antibody)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Incyte Corporation	Phase 2
NCT04084080	Sickle Cell Disease and Cardiovascular Risk - Red Cell Exchange Trial (SCD-CARRE)	Sickle Cell Disease	Biological: Red Blood Cell Other: Standard of care	Mark Gladwin National Heart, Lung, and Blood Institute (NHLBI) University of Pittsburgh	Phase 3
NCT04073160	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer	Bladder Cancer	Drug: Tremelimumab Drug: Durvalumab Radiation: Bladder radiation Drug: Intravesicular Therapy	Daniel George, MD AstraZeneca Duke University	Phase 1
NCT04059588	A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin	Cancer Solid Tumor Cancer of Skin	Drug: 2141 V-11	Rockefeller University	Phase 1
NCT04049383	CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL	Acute Lymphoblastic Leukemia, in Relapse Acute Lymphoblastic Leukemia With Failed Remission Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia Not Having Achieved Remission Acute Lymphoblastic Leukemia, Pediatric Acute Lymphoblastic Leukemia	Biological: CAR-20/19-T cells	Medical College of Wisconsin Children's Hospital and Health System Foundation, Wisconsin	Phase 1
NCT04044534	Intranasal Insulin for Posttraumatic Stress Disorder	PTSD	Drug: Intranasal insulin Drug: Placebo	VA Connecticut Healthcare System	Phase 2
NCT04032418	Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer	Lung Non-Small Cell Carcinoma	Biological: Pembrolizumab	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04030052	Emicizumab PUPs and Nuwiq ITI Study	Hemophilia A	Drug: Nuwiq (low dose protocol) Drug: Emicizumab Drug: Nuwiq (Atlanta protocol)	Emory University	Phase 3
NCT04015700	Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma	Glioblastoma	Biological: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics Device: CELLECTRA 2000 EP Device supplied by Geneos Therapeutics Drug: Plasmid encoded IL-12	Washington University School of Medicine	Phase 1
NCT03961815	Open-label Extension Study of Brazikumab in Crohn's Disease	Crohn's Disease	Drug: Brazikumab	Allergan	Phase 3
NCT03920631	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas	B Cell Lymphomas	Drug: Nivolumab Biological: Microtransplantation	Ahmed Galal, MD Duke University	Phase 1
NCT03840343	Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Diabetic Kidney Disease Diabetic Nephropathies Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Chronic Kidney Disease Diabetic Nephropathy Type 2 Kidney Failure Kidney Insufficiency	Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose	Mayo Clinic Regenerative Medicine Minnesota	Phase 1
NCT03835819	A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)	Endometrial Cancer	Drug: Pembrolizumab Drug: IMGN853	Dana-Farber Cancer Institute ImmunoGen, Inc. Merck Sharp & Dohme Corp.	Phase 2

# 해외 바이오의약품 임상 현황 (2019.12.24~2020.01.06)

한국바이오의약품협회, 2020.1.7.  
출처: ClinicalTrials.gov

NCT03807063	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant	Acute Bilineal Leukemia Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myeloproliferative Neoplasm Recurrent Acute Biphentotypic Leukemia Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome	Biological: Rivogenlecleucel Drug: Rimiducid	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Bellicum Pharmaceuticals	Phase 1
NCT03706274	PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors	Solid Tumor, Adult	Drug: CX-188	CytomX Therapeutics	Phase 1
NCT03624062	MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes	Type 1 Diabetes Mellitus	Drug: MAS-1 adjuvanted Insulin B-chain	University of Colorado, Denver The Leona M. and Harry B. Helmsley Charitable Trust Nova Immunotherapeutics Limited	Phase 1
NCT03258658	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT02194751	Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma	Follicular Lymphoma	Biological: Oncoquest-L vaccine	XEME Biopharma Inc.	Phase 2
NCT02035085	19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction	Breast Cancer	Drug: CS-1000 labeled SVF cells	Johns Hopkins University Cosmeticsurg.net	Phase 1
NCT04201145	Pembrolizumab + Defactinib In Pleural Mesothelioma	Malignant Pleural Mesothelioma	Drug: Pembrolizumab Drug: Defactinib	Raphael Bueno, MD Merck Sharp & Dohme Corp. Dana-Farber Cancer Institute	Phase 1
NCT04148352	Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy	Allergies Food Milk	Drug: Dupilumab Other: Placebo	Andrew J Long, PharmD Stanford University	Phase 2
NCT04118036	Abemaciclib + Pembrolizumab In Glioblastoma	Glioblastoma	Drug: Pembrolizumab Drug: Abemaciclib	Dana-Farber Cancer Institute	Phase 2
NCT03920878	Cataract DME - Peri vs. Intraop	Diabetic Macular Edema Cataract	Drug: Aflibercept injected Pre- and Post-operatively Drug: Aflibercept injected intraoperatively	Emory University	Phase 2
NCT03607955	Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer	Drug: AVB-S6-500 Drug: Paclitaxel Drug: Carboplatin Procedure: Tissue from Diagnostic Laparoscopy Procedure: Tissue from Core biopsy Procedure: Interval Debulking Procedure: Peripheral blood Procedure: Ascites collection	Washington University School of Medicine Aravive, Inc.	Phase 1
NCT04123470	A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma	Malignant Melanoma	Genetic: delolimogene mupadenorepvec Biological: atezolizumab	Lokon Pharma AB Precision Oncology LLC	Phase 1 Phase 2
NCT04197596	Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)	Viral Infection Primary Immune Deficiency Disorder	Biological: BK CTL	New York Medical College Children's Hospital of Philadelphia Medical College of Wisconsin Nationwide Children's Hospital	Phase 1 Phase 2
NCT04144335	N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV	Hiv HIV/AIDS HIV Infections AIDS AIDS and Infections Aids/Hiv Problem	Biological: N-803 and bNABs Biological: haNK??Cells	University of Minnesota	Phase 1 Phase 2
NCT04213261	A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa	Recessive Dystrophic Epidermolysis Bullosa	Biological: FCX-007 (no generic name is established; see below for FCX-007 description)	Fibrocell Technologies, Inc. Castle Creek Pharmaceuticals, LLC	Phase 3
NCT04157127	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma	Pancreatic Adenocarcinoma Pancreatic Cancer	Biological: Autologous DC vaccine	Baylor College of Medicine Cancer Cures for Kids	Phase 1
NCT04124042	Efficacy and Safety of XT-150 in Osteoarthritis of the Knee	Osteoarthritis, Knee	Biological: XT-150	Xalud Therapeutics, Inc.	Phase 2
NCT03804944	Converting HR+ Breast Cancer Into an Individualized Vaccine	Breast Cancer	Radiation: Focal Radiation therapy Drug: Pembrolizumab (200mg IV for 30 minutes) Biological: CDX-301	Weill Medical College of Cornell University	Phase 2
NCT04084951	Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Adult Solid Tumor	Biological: SQZ-PBMC-HPV Drug: Atezolizumab	SQZ Biotechnologies	Phase 1
NCT04052204	Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors	Squamous Cell Carcinoma of the Head and Neck (SCCHN) Metastatic Castration Resistant Prostate Cancer (mCRPC)	Drug: avelumab Drug: Bempegaldesleukin Drug: talazoparib Drug: enzalutamide	Pfizer EMD Serono Nektar Therapeutics Astellas Pharma Inc	Phase 2
NCT03992456	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	BRAF V600 Wild Type KRAS Gene Mutation Negative Metastatic Colon Adenocarcinoma Metastatic Colorectal Carcinoma Metastatic Rectal Adenocarcinoma NRAS Gene Mutation Negative Progressive Disease RAS Wild Type Stage IV Colon Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Rectal Cancer AJCC v8 Stage IVA Colon Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Rectal Cancer AJCC v8 Stage IVB Colon Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Rectal Cancer AJCC v8 Stage IVC Colon Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVC Rectal Cancer AJCC v8	Biological: Panitumumab Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Regorafenib Drug: Trifluridine and Tipiracil Hydrochloride	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04119050	Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia	Warm Autoimmune Hemolytic Anemia	Drug: M281 Drug: Placebo	Momenta Pharmaceuticals, Inc.	Phase 2 Phase 3
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2

## 해외 바이오의약품 임상 현황 (2019.12.24~2020.01.06)

한국바이오약품협회, 2020.1.7.  
출처: ClinicalTrials.gov

NCT04132817	A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread	Breast Cancer	Drug: nivolumab Drug: ipilimumab Drug: nab-paclitaxel	Bristol-Myers Squibb	Phase 1
NCT04096950	Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury	Spinal Cord Injury	Biological: MT-3921 Low dose Biological: MT-3921 High dose	Mitsubishi Tanabe Pharma Development America, Inc.	Phase 1
NCT03989206	Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis	Moderate-to-Severe Atopic Dermatitis	Drug: Nemolizumab	Galderma R&D	Phase 3
NCT03739996	Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1	HIV Infections	Drug: Oral Cabotegravir (CAB) Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Drug: Long-Acting Injectable Cabotegravir (CAB LA) Biological: VRC07-523LS Drug: Standard of Care (SOC) Oral ART	National Institute of Allergy and Infectious Diseases (NIAID) ViiV	Phase 2
NCT04148937	A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer	Advanced Cancer	Drug: LY3475070 Drug: Pembrolizumab	Eli Lilly and Company	Phase 1

### ○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04075331	Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial	COPD Eosinophilia	Drug: Mepolizumab Drug: Placebo	University of Leicester Leicester Clinical Trials Unit GlaxoSmithKline	Phase 2 Phase 3
NCT04166734	Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma	Advanced Malignant Pleural Mesothelioma	Drug: Pembrolizumab Radiation: Stereotactic Body Radiotherapy (SBRT)	Royal Marsden NHS Foundation Trust Merck Sharp & Dohme Corp.	Phase 1
NCT03996473	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Carcinoma, Non-Small-Cell Lung	Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Drug: Pembrolizumab	Bayer	Phase 1 Phase 2

### ○ 프랑스 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04065152	Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma	Kaposi Sarcoma	Drug: Talimogene laherparepvec	Assistance Publique - Hôpital de Paris	Phase 2
NCT04013620	CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction	Chronic Kidney Failure	Drug: Belatacept 250 Milligram Intravenous Powder for Solution	Nantes University Hospital	Phase 3
NCT04217473	TNFAlpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma	Metastatic Melanoma	Biological: TILT-123	TILT Biotherapeutics Ltd.	Phase 1
NCT03955198	A Study Evaluating the Efficacy of the Combination of Hypofractionated Stereotactic Radiation Therapy With the Anti-PDL1 Immune Checkpoint Inhibitor Durvalumab in NSCLC Patients With 1 to 4 Brain Metastases	Brain Metastases NSCLC	Radiation: Radiotherapy Combination Product: Radiotherapy + durvalumab	Institut Claudius Regaud	Phase 2
NCT04202705	A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875	Solid Tumor	Drug: SYD1875	Synthon Biopharmaceuticals BV	Phase 1
NCT04180085	Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)	Heart Transplant Failure	Drug: Belatacept Injection	Nantes University Hospital	Phase 2
NCT04169841	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	Immunotherapy	Drug: olaparib, durvalumab, tremelimumab	Centre Georges Francois Leclerc AstraZeneca	Phase 2

### ○ 독일 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04161976	A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus	Diabetes Mellitus, Type 1	Drug: LY900027 Drug: Insulin Lispro	Eli Lilly and Company	Phase 1
NCT04200755	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma	Localized Scleroderma	Drug: Dupilumab 300Mg Solution for Injection Other: Placebo	University of Cologne	Phase 2
NCT04205552	Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients	NSCLC Stage II NSCLC, Stage IIIA NSCLC, Stage I	Drug: Nivolumab 10 MG/ML Intravenous Solution Drug: Relatlimab 10 MG/ML Intravenous Solution	University Hospital, Essen	Phase 2
NCT03996473	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Carcinoma, Non-Small-Cell Lung	Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Drug: Pembrolizumab	Bayer	Phase 1 Phase 2

### ○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04176016	Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma	Relapsed or Refractory Synovial Sarcoma	Drug: OTSA101-DTPA-111In Drug: OTSA101-DTPA-90Y	OncoTherapy Science, Inc.	Phase 1

# 해외 바이오의약품 임상 현황 (2019.12.24~2020.01.06)

한국바이오의약품협회, 2020.1.7.  
출처: ClinicalTrials.gov

## ○ 중국 13건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04213248	Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD	Dry Eye	Drug: Umbilical Mesenchymal Stem Cells derived Exosomes	Zhongshan Ophthalmic Center, Sun Yat-sen University	Phase 1 Phase 2
NCT04138992	A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	Disease Free Survival	Drug: bevacizumab Drug: DDP Drug: Docetaxel Radiation: radiotherapy	Fourth Military Medical University	Phase 2 Phase 3
NCT04214626	R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma	Diffuse Large B Cell Lymphoma	Drug: Rituximab Drug: Lenalidomide Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone Drug: Methotrexate	Henan Cancer Hospital	Phase 2
NCT04207463	A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors	Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors	Drug: AK105 Drug: Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
NCT04203719	A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer	Advanced Head, Neck and Chest Cancer	Drug: AK105 Drug: Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2
NCT04165993	Study of KN026 Monotherapy or Combined With Chemotherapy in Patients With Metastatic Breast Cancer	Metastatic Breast Cancer	Drug: KN026 combination Drug: KN026 monotherapy	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Phase 2
NCT04151810	Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors	Advanced Tumors	Drug: CDP1	Dragonboat Biopharmaceutical Company Limited	Phase 1
NCT04129710	A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)	Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)	Drug: Ibrutinib Drug: Lenalidomide Drug: Methotrexate Drug: Rituximab Drug: Etoposide Drug: PEGylated recombinant human granulocyte colony	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
NCT04025931	A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma	Sarcoma	Drug: chidamide and toripalimab	Sun Yat-sen University	Phase 2
NCT03902067	UC-MSC Transplantation for Left Ventricular Dysfunction After AMI	Left Ventricular Dysfunction Acute Myocardial Infarction	Biological: UC-MSC Biological: Control Group	Shanghai Life Science & Technology Shanghai Jiao Tong University Affiliated Sixth People's Hospital	Phase 1
NCT04178460	A Study of Niraparib Combined With MGD013 in Gastric/Gastroesophageal Junction Cancer	Gastric Cancer	Drug: Niraparib combined with MGD013	Zai Lab (Shanghai) Co., Ltd.	Phase 1
NCT04158947	A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone	HER2-positive Breast Cancer Brain Metastases	Drug: Afatinib Drug: T-DM1	xuexin he Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
NCT04060888	A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus	Lupus Erythematosus, Systemic	Drug: Ustekinumab (approximately 6 mg/kg) Drug: Ustekinumab 90 milligram (mg) Drug: Placebo	Janssen Research & Development, LLC	Phase 3